Potentials of C-C motif chemokine 2–C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents

Kanae Yumimoto, Shigeaki Sugiyama, Koshi Mimori, Keiichi Nakayama

研究成果: ジャーナルへの寄稿評論記事

抄録

Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.

元の言語英語
ページ(範囲)2090-2099
ページ数10
ジャーナルCancer Science
110
発行部数7
DOI
出版物ステータス出版済み - 7 1 2019

Fingerprint

C Chemokines
CC Chemokines
Chemokine Receptors
Antineoplastic Agents
Inflammation
Neoplasms
Chemokine CCL2
Hepatitis B
Japan
Pharmacology
proxigermanium

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Potentials of C-C motif chemokine 2–C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents. / Yumimoto, Kanae; Sugiyama, Shigeaki; Mimori, Koshi; Nakayama, Keiichi.

:: Cancer Science, 巻 110, 番号 7, 01.07.2019, p. 2090-2099.

研究成果: ジャーナルへの寄稿評論記事

@article{827ea48084004a26bdae92dd539eaebb,
title = "Potentials of C-C motif chemokine 2–C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents",
abstract = "Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.",
author = "Kanae Yumimoto and Shigeaki Sugiyama and Koshi Mimori and Keiichi Nakayama",
year = "2019",
month = "7",
day = "1",
doi = "10.1111/cas.14075",
language = "English",
volume = "110",
pages = "2090--2099",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Potentials of C-C motif chemokine 2–C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents

AU - Yumimoto, Kanae

AU - Sugiyama, Shigeaki

AU - Mimori, Koshi

AU - Nakayama, Keiichi

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.

AB - Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.

UR - http://www.scopus.com/inward/record.url?scp=85068553751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068553751&partnerID=8YFLogxK

U2 - 10.1111/cas.14075

DO - 10.1111/cas.14075

M3 - Review article

C2 - 31111571

AN - SCOPUS:85068553751

VL - 110

SP - 2090

EP - 2099

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -